NHS funding for EUSA’s Pharma’s Qarziba has been approved to treat children with high-risk neuroblastoma.
News
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial
AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma.
Pfizer re-organises into three business units
Pfizer has announced a re-organisation of its operations into three distinct businesses.
NICE backs use of dye for brain tumour removal
NICE has published new guidelines recommending use of a chemical dye to assist neurosurgeons in removing brain tumours.
NHS England appoints national clinical advisor for primary care
NHS England has appointed a specialist GP to encourage the spread of innovations that integrate health and social care throughout England.
Janssen launches PhII/III programme testing Tremfya in Crohn’s
Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn’s Disease.
Gov’t launches £10 antimicrobial research competition
The government has launched a £10 million research competition to encourage the development of novel approaches to combating antimicrobial resistance and improving infection prevention and control.
Takeda gets US nod for Shire buy
Takeda says it has received unconditional clearance from the US Federal Trade Commission for the proposed acquisition of Shire.
NICE advises restricted use of antibiotics for COPD
The National Institute for Health and Care Excellence is advising healthcare professionals to restrict use of antibiotics for chronic obstructive pulmonary disease (COPD).
CTI, Servier’s Pixuvri fails in post-marketing trial
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche’s MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Three cancer treatments approved for use on NHS Scotland
Three treatments have been approved for NHS funding in Scotland, bringing new options for gastroenteropancreatic tumours, lung and kidney cancers, but patients with multiple sclerosis will be unable to access Roche’s Ocrevus following a rejection by the SMC.
May names Hancock as new health and social care secretary
Prime Minister Theresa May has named West Suffolk MP Matt Hancock as the new secretary of state for health and social care.
NHS England clears specialised treatments for NHS use
NHS England has approved routine funding for a stream of new specialised treatments, including stroke-reducing heart implants and a life changing surgical procedure for children with cerebral palsy.
Vertex, NHS England no closer to Orkambi settlement
Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement that would allow patients access to the drug on the NHS.
PAH patients in England denied access to Actelion’s Uptravi on NHS
Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
